Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.
AIMS Incretin-based pharmacotherapy was initially developed to improve glucose-dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next-generation polyagonist develop...